Potential adverse effects of proton pump inhibitors

Current Gastroenterology Reports

Volumn 10, Issue 3, 2008, Pages 208-214

  Coté, Gregory A ^a   Howden, Colin W ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CALCIUM; GASTRIN; HISTAMINE H2 RECEPTOR ANTAGONIST; IMMUNOSUPPRESSIVE AGENT; OMEPRAZOLE; PROTON PUMP INHIBITOR;

BACTERIAL INFECTION; BONE METABOLISM; BONE TURNOVER; CALCIUM ABSORPTION; CLINICAL TRIAL; CLOSTRIDIUM DIFFICILE; COLITIS; COLON CARCINOGENESIS; COLORECTAL CANCER; COMMUNITY ACQUIRED PNEUMONIA; COMORBIDITY; CORRELATIONAL STUDY; CYANOCOBALAMIN DEFICIENCY; DIET SUPPLEMENTATION; DISEASE COURSE; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENCY; DRUG SAFETY; DRUG USE; ESOPHAGITIS; GALLBLADDER DISEASE; GASTROENTERITIS; GASTROESOPHAGEAL REFLUX; HIGH RISK PATIENT; HIP FRACTURE; HUMAN; HYPERGASTRINEMIA; INFECTION RISK; INTERSTITIAL NEPHRITIS; INTESTINE INFECTION; IRON ABSORPTION; IRON DEFICIENCY; LONG TERM CARE; LOW DRUG DOSE; MALABSORPTION; METABOLIC BONE DISEASE; NONHUMAN; PATHOPHYSIOLOGY; PATIENT MONITORING; PEPTIC ULCER; PRESCRIPTION; RECOMMENDED DRUG DOSE; REVIEW; RISK ASSESSMENT; RISK FACTOR; SPINE FRACTURE; STOMACH ADENOCARCINOMA; STOMACH CARCINOGENESIS; STOMACH CARCINOID; SYMPTOM; TREATMENT DURATION; VITAMIN D DEFICIENCY;

GASTROESOPHAGEAL REFLUX; HUMANS; PROTON PUMP INHIBITORS; RISK ASSESSMENT;

EID: 54049091656     PISSN: 15228037     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11894-008-0045-4     Document Type: Review

References (50)

1. Shaheen NJ, Hansen RA, Morgan DR, et al.: The burden of gastrointestinal and liver diseases, 2006. Am J Gastroenterol 2006, 101:2128-2138.
2. Laine L, APnen D, McClain C, et al.: Review article: potential gastrointestinal effects of long-term acid suppression with proton pump inhibitors. Aliment Pharmacol Ther 2000, 14:651-668.
3. Hill AB: The environmenA and disease: association or causation? Proc R Soc Med 1965, 58:295-300.
4. Thorens J, Froehlich F, Schwizer W, et al.: Bacterial over-growth during treatment with omeprazole compared with cimetidine: A prospective randomised double blind study. Gut 1996, 39:54-59.
5. Dial S, Alrasadi K, Manoukian C, et al.: Risk of Clostridium difficile diarrhea among hospital impatients prescribed proton pump inhibitors: cohort and case-control studies. CMAJ 2004, 171:33-38.
6. Leonard J, Marshall JK, Moayyedi P: Systematic review of the risk of enteric infection in patients taking acid suppression. Am J Gastroenterol 2007, 102: 2047-2056; quiz 2057.
7. Shah S, Lewis A, Leopold D, et al.: Gastric acid suppression does not promote clostridial diarrhoea in the elderly. QJM 2000, 93:175-181.
8. Loo VG, Poirier L, Miller MA, et al.: A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med 2005, 353:2442-2449.
9. Laheij RJ, Sturkenboom MC, Hassing RJ, et al.: Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. JAMA 2004, 292:1955-1960.
10. Gulmez SE, Holm A, Frederiksen H, et al.: Use of proton pump inhibitors and the risk of community-acquired pneumonia: A population-based case-control study. Arch Intern Med 2007, 167:950-955.
11. Laheij RJ, Van Ijzendoorn MC, Janssen MJ, Jansen JB: Gastric acid-suppressive therapy and community-acquired respiratory infections. Aliment Pharmacol Ther 2003, 18:847-851.
12. Canani RB, Cirillo P, Roggero P, et al.: Therapy with gastric acidity inhibitors increases the risk of acute gastroenteritis and community-acquired pneumonia in children. Pediatrics 2006, 117:e817-e820.
13. Sarkar MA, Yang YX: Are proton pump inhibitors (PPIs) associated with an increased risk of community-acquired pneumonia (CAP)? A nested case control study investigating recent PPI exposure and CAP [abstract]. Am J Gastroenterol 2007, 102:S446.
14. Chonan O, Takahashi R, Yasui H, Watanuki M: Effect of L-lactic acid on calcium absorption in rats fed omeprazole. J Nutr Sci Vitaminol (Tokyo) 1998, 44:473-481.
15. Bo-Linn GW, Davis GR, Buddrus DJ, et al.: An evaluation of the importance of gastric acid secretion in the absorption of dietary calcium. J Clin Invest 1984, 73:640-647.
16. Recker RR: Calcium absorption and achlorhydria. N Engl J Med 1985, 313:70-73.
17. O'Connell MB, Madden DM, Murray AM, et al.: Effects of proton pump inhibitors on calcium carbonate absorption in women: A randomized crossover trial. Am J Med 2005, 118:778-781.
18. Mattsson JP, Vaananen K, Wallmark B, Lorentzon P: Omeprazole and bafilomycin, two proton pump inhibitors: Differentiation of their effects on gastric, kidney and bone H(+)-translocating ATPases. Biochim Biophys Acta 1991, 1065:261-268.
19. Kocsis I, Arato A, Bodanszky H, et al.: Short-term omeprazole treatment does not influence biochemical parameters of bone turnover in children. Calcif Tissue Int 2002, 71:129-132.
20. Mizunashi K, Furukawa Y, Katano K, Abe K: Effect of omeprazole, an inhibitor of H+,K(+)-ATPase, on bone resorption in humans. Calcif Tissue Int 1993, 53:21-25.
21. Hollowell J: The General Practice Qesearch Database: quality of morbidity data. Popul Trends 1997, Spring: 36-40.
22. Yang YX, Lewis JD, Epstein S, Metz DC: Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA 2006, 296:2947-2953.
23. Geller JL, Adams JS: Proton pump inhibitor therapy and hip fracture risk. JAMA 2007, 297: 1429; author reply 1429-1430.
24. Vestergaard P, Rejnmark L, Mosekilde L: Proton pump inhibitors, histamine H2 receptor antagonists, and other antacid medications and the risk of fracture. Calcif Tissue Int 2006, 79:76-83.
25. Howden CW: Vitamin B12 levels during prolonged treatment with proton pump inhibitors. J Clin Gastroenterol 2000, 30:29-33.
26. Schenk BE, Festen HP, Kuipers EJ, et al.: Effect of short-and long-term treatment with omeprazole on the absorption and serum levels of cobalamin. Aliment Pharmacol Ther 1996, 10:541-545.
27. Koop H, Bachem MG: Serum iron, ferritin, and vitamin B12 during prolonged omeprazole therapy. J Clin Gastroenterol 1992, 14:288-292.
28. Valuck RJ, Ruscin JM: A case-control study on adverse effects: H2 blocker or proton pump inhibitor use and risk of vitamin B12 deficiency in older adults. J Clin Epidemiol 2004, 57:422-428.
29. Force RW, Meeker AD, Cady PS, et al.: Ambulatory care increased vitamin B12 requirement associated with chronic acid suppression therapy. Ann Pharmacother 2003, 37:490-493.
30. Hutchinson C, Geissler CA, Powell JJ, Bomford A: Proton pump inhibitors suppress absorption of dietary non-haem iron in hereditary haemochromatosis. Gut 2007, 56:1291-1295.
31. Stewart CA, Termanini B, Sutliff VE, et al.: Iron absorption in patients with Zollinger-Ellison syndrome treated with long-term gastric acid antisecretory therapy. Aliment Pharmacol Ther 1998, 12:83-98.
32. Larsson H, Carlsson E, Mattsson H, et al.: Plasma gastrin and gastric enterochromaffinlike cell activation and proliferation. Studies with omeprazole and ranitidine in intact and antrectomized rats. Gastroenterology 1986, 90:391-399.
33. Rindi G, Luinetti O, Cornaggia M, et al.: Three subtypes of gastric argyrophil carcinoid and the gastric neuroendocrine carcinoma: A clinicopathologic study. Gastroenterology 1993, 104:994-1006.
34. Peghini PL, Annibale B, Azzoni C, et al.: Effect of chronic hypergastrinemia on human enterochromaffin-like cells: Insights from patients with sporadic gastrinomas. Gastroenterology 2002, 123:68-85.
35. Modlin IM, Lye KD, Kidd M: A 50-year analysis of 562 gastric carcinoids: small tumor or larger problem? Am J Gastroenterol 2004, 99:23-32.
36. Lamberts R, Brunner G, Solcia E: Effects of very long (up to 10 years) proton pump blockade on human gastric mucosa. Digestion 2001, 64:205-213.
37. Solcia E, Fiocca R, Havu N, et al.: Gastric endocrine cells and gastritis in patients receiving long-term omeprazole treatment. Digestion 1992, 51(Suppl 1):82-92.
38. Klinkenberg-Knol EC, Nelis F, Dent J, et al.: Long-term omeprazole treatment in resistant gastroesophageal reflux disease: Efficacy, safety, and influence on gastric mucosa. Gastroenterology 2000, 118:661-669.
39. Eslick GD, Lim LL, Byles JE, et al.: Association of Helicobacter pylori infection with gastric carcinoma: A meta-analysis. Am J Gastroenterol 1999, 94:2373-2379.
40. Kuipers EJ, Nelis GF, Klinkenberg-Knol EC, et al.: Cure of Helicobacter pylori infection in patients with reflux oesophagitis treated with long term omeprazole reverses gastritis without exacerbation of reflux disease: Results of a randomised controlled trial. Gut 2004, 53:12-20.
41. Kuipers EJ: Proton pump inhibitors and gastric neoplasia. Gut 2006, 55:1217-1221.
42. Watson SA, Smith AM: Hypergastrinemia promotes adenoma progression in the APC(Min-/+) mouse model of familial adenomatous polyposis. Cancer Res 2001, 61:625-631.
43. Thorburn CM, Friedman GD, Dickinson CJ, et al.: Gastrin and colorectal cancer: A prospective study. Gastroenterology 1998, 115:275-280.
44. Yang YX, Hennessy S, Propert K, et al.: Chronic proton pump inhibitor therapy and the risk of colorectal cancer. Gastroenterology 2007, 133:748-754.
45. Robertson DJ, Larsson H, Friis S, et al.: Proton pump inhibitor use and risk of colorectal cancer: A population-based, case-control study. Gastroenterology 2007, 133:755-760.
46. Cahan MA, Balduf L, Colton K, et al.: Proton pump inhibitors reduce gallbladder function. Surg Endosc 2006, 20:1364-1367.
47. Chowdhury JR, Berkowitz JM, Praissman M, Fara JW: Effect of sulfated and non-sulfated gastrin and octapeptide-cholecystokinin on cat gall bladder in vitro. Experientia 1976, 32:1173-1175.
48. Geevasinga N, Coleman PL, Webster AC, Roger SD: Proton pump inhibitors and acute interstitial nephritis. Clin Gastroenterol Hepatol 2006, 4:597-604.
49. Sierra F, SuaPez M, Rey M, Vela MF: Systematic review: proton pump inhibitor-associated acute interstitial nephritis. Aliment Pharmacol Ther 2007, 26:545-553.
50. Cote GA, Ferreira MR, Rozenberg-Ben-Dror K, Howden CW: Programme of stepping down from twice daily proton pump inhibitor therapy for symptomatic gastro-oesophageal reflux disease associated with a formulary change at a VA medical center. Aliment Pharmacol Ther 2007, 25:709-714.